3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Glioma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Refractory Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Pancreatic Diseases
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Metastatic Pancreatic Adenocarcinoma
1
Mesothelioma
1
Malignant Solid Neoplasm
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Interventions
Gemcitabine
8
Oxaliplatin
6
Irinotecan
6
Leucovorin
5
Cisplatin
5
Radiotherapy
4
Fluorouracil
4
Capecitabine
4
pembrolizumab
3
Interleukin-12 Subunit p35
3
Erlotinib Hydrochloride
3
Trastuzumab
2
Carboplatin
2
tipifarnib
1
spartalizumab
1
ricolinostat
1
motexafin gadolinium
1
irinotecan sucrosofate
1
entinostat
1
dehydroftorafur
1
Thalidomide
1
Protein Subunit Vaccines
1
Positron Emission Tomography Computed Tomography
1
Polymerase Chain Reaction
1
Platinum
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
Paclitaxel
1
Microarray Analysis
1
Mesna
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Bile Duct Neoplasms
×
irinotecan sucrosofate
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled